Table 2.
Laboratory data | UCG data | |||
DGLA (mg/mL) | 37.4±14.5 (13.6-79.1) | LVIVS (mm) | 10.1±2.1 (6-16) | |
AA (mg/mL) | 176.6±42.7 (96.9-269.1) | LVPW (mm) | 10.4±1.8 (7-15) | |
DGLA+AA (mg/mL) | 211.9±55.3 (72-323.2) | LVDD (mm) | 62.1±10.7 (43-92) | |
EPA (mg/mL) | 46.7±29.1 (8-155.7) | LVDS (mm) | 53.7±11.4 (55-81) | |
DHA (mg/mL) | 114.6±44.8 (10.3-208.9) | LVEF (%) | 29.6±9.8 (10-57) | |
EPA+DHA (mg/mL) | 161.3±69.9 (35.7-351.1) | |||
EPA/AA | 0.27±0.16 (0.05-0.74) | CPET data | ||
(EPA+DHA/AA) | 1.00±0.69 (0.18-5.00) | Peak VO2 (mL/kg/min) | 17.0±3.9 (8.1-29.1) | |
(EPA+DHA)/(DGLA+AA) | 0.79±0.43 (0.14-2.92) | %ppVO2 (%) | 65.0±14.2 (31-90) | |
AA/DGLA | 5.14±1.90 (1.4-10.8) | VE/VCO2 slope | 30.5±6.9 (19.2-50.9) | |
NT-pro BNP (pg/mL) | 1,185.8±999.2 (109.6-4,024) | |||
Hb (g/dL) | 15.1±1.8 (10.4-18.8) | |||
eGFR (mL/min/1.73m2) | 64.3±16.2 (37.3-108.4) | |||
TC (mg/dL) | 179.4±36.9 (101.4-265) | |||
LDL-C (mg/dL) | 107.4±28.0 (61-197) | |||
HDL-C (mg/dL) | 44.3±12.2 (12-85) | |||
TG (mg/dL) | 138.4±76.8 (36-416) | |||
HbA1c (%) | 6.2±1.0 (5.2-10.1) | |||
Alb (g/dL) | 4.0±0.5 (2.3-4.7) | |||
CRP (mg/dL) | 0.29±0.48 (0.02-2.23) |
Values presented as n (%) or means±SD. DGLA: dihomo-γ-linolenic acid, AA: arachidonic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid, NT-pro BNP: N-terminal pro-brain natriuretic peptide, Hb: hemoglobin, eGFR: estimate glomerular filtration rate, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, HbA1c: hemoglobin A1c, Alb: albumen, CRP: C-reactive protein, UCG: ultrasonic echocardiography, IVS: interventricular septum, LVPW: left ventricular posterior wall, LVDD: left ventricular internal dimension in diastole, LVDS: left ventricular diameter at end systole, EF: ejection fraction, CPET: cardiopulmonary exercise test, peak VO2: peak oxygen uptake, %ppVO2: percent predicted peak VO2, VE/VCO2 slope: regression slope relating minute ventilation to carbon dioxide output